John R. Plachetka, the chairman and chief executive officer of POZEN Incorporated (NASD: POZN), a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs, presented earlier this week at the UBS Global Life Sciences Conference in New York, New York.

The company’s research and development efforts are focused primarily on the development and commercialization of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. The company focuses on providing therapeutic advancements that can improve efficacy, safety, and/or patient convenience. POZEN currently has development and commercialization alliances with GlaxoSmithKline for Treximet™, a treatment that was approved by the U.S. FDA for the acute relief of migraine attacks in adults. Under the terms of the agreement, POZEN will receive royalties based on net sales from GlaxoSmithKline.

At the conference, Dr. Plachetka commented, “We are currently making single-digit royalties on Treximet™ today, but beginning in 2010, we will be making high teens royalties. We are just now beginning to see the direct advertising for this product by GlaxoSmithKline. Already it has outperformed the launch of Pfizer’s Relpax® by a significant amount. Treximet™ is taking market share from the entire space.”

Let us hear your thoughts below: